热门话题-Truist分析师：Lantheus 70亿美元估值或‘偏低’

路透中文

May 26

热门话题-Truist分析师：Lantheus 70亿美元估值或‘偏低’

5月26日 - 据彭博社周五报导，核医学公司Lantheus Holdings（LNTH.O）正在考虑潜在的出售事宜，其估值约为70亿美元(link)，此前由私募股权支持的Curium Pharma提出了收购要约

** Truist分析师表示，与该公司目前约67亿美元的市值相比，70亿美元的估值显得“偏低”

** Truist指出，LNTH将补充Curium在神经内分泌癌和前列腺癌领域已有的放射性药物产品组合

** 美国食品药品监督管理局（FDA）于3月批准了Lantheus公司成像剂Pylarify TruVu的新剂型(link)，用于检测前列腺癌

** Truist表示，LNTH仍“在多元化增长动力的推动下，是一个被低估且极具吸引力的营收/利润增长重启故事”，且其PET成像业务线的报销前景正在改善

** 该券商表示，投资者会将每股115至125美元视为“更易接受的溢价/收购价位”

** 截至上周五收盘，该股年内累计涨幅近55%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2638187335"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2638187335\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2638187335?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-05-26 17:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638187335","market":"hk","top_or_hot":-1,"title":"热门话题-Truist分析师：Lantheus 70亿美元估值或‘偏低’","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>热门话题-Truist分析师：Lantheus 70亿美元估值或‘偏低’</title></head><body><p>\n<span>5月26日</span><span> - </span>据彭博社周五报导，核医学公司Lantheus Holdings（<span>LNTH.O</span>）正在考虑潜在的出售事宜，其估值约为70亿美元(<span>link</span>)，此前由私募股权支持的Curium Pharma提出了收购要约</p><p>** Truist分析师表示，与该公司目前约67亿美元的市值相比，70亿美元的估值显得“偏低”</p><p>** Truist指出，LNTH将补充Curium在神经内分泌癌和前列腺癌领域已有的放射性药物产品组合</p><p>** <a href=\"https://laohu8.com/S/USFD\">美国食品</a>药品监督管理局（FDA）于3月批准了Lantheus公司成像剂Pylarify TruVu的新剂型(<span>link</span>)，用于检测前列腺癌 </p><p>** Truist表示，LNTH仍“在多元化增长动力的推动下，是一个被低估且极具吸引力的营收/利润增长重启故事”，且其PET成像业务线的报销前景正在改善</p><p>** 该券商表示，投资者会将每股115至125美元视为“更易接受的溢价/收购价位”</p><p>** 截至上周五收盘，该股年内累计涨幅近55% </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>热门话题-Truist分析师：Lantheus 70亿美元估值或‘偏低’</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n热门话题-Truist分析师：Lantheus 70亿美元估值或‘偏低’\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-05-26 17:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>热门话题-Truist分析师：Lantheus 70亿美元估值或‘偏低’</title></head><body><p>\n<span>5月26日</span><span> - </span>据彭博社周五报导，核医学公司Lantheus Holdings（<span>LNTH.O</span>）正在考虑潜在的出售事宜，其估值约为70亿美元(<span>link</span>)，此前由私募股权支持的Curium Pharma提出了收购要约</p><p>** Truist分析师表示，与该公司目前约67亿美元的市值相比，70亿美元的估值显得“偏低”</p><p>** Truist指出，LNTH将补充Curium在神经内分泌癌和前列腺癌领域已有的放射性药物产品组合</p><p>** <a href=\"https://laohu8.com/S/USFD\">美国食品</a>药品监督管理局（FDA）于3月批准了Lantheus公司成像剂Pylarify TruVu的新剂型(<span>link</span>)，用于检测前列腺癌 </p><p>** Truist表示，LNTH仍“在多元化增长动力的推动下，是一个被低估且极具吸引力的营收/利润增长重启故事”，且其PET成像业务线的报销前景正在改善</p><p>** 该券商表示，投资者会将每股115至125美元视为“更易接受的溢价/收购价位”</p><p>** 截至上周五收盘，该股年内累计涨幅近55% </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nL4T4230JN:1","article_id":"2638187335","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638187335","pubTimestamp":1779789481,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4198":"医疗保健用品","LNTH":"Lantheus Holdings, Inc."},"translate_title":"Hot Topics-Truist Analyst: Lantheus $7 Billion Valuation Or 'On The Low Side'","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LNTH":0.9},"content_text":"热门话题-Truist分析师：Lantheus 70亿美元估值或‘偏低’\n5月26日 - 据彭博社周五报导，核医学公司Lantheus Holdings（LNTH.O）正在考虑潜在的出售事宜，其估值约为70亿美元(link)，此前由私募股权支持的Curium Pharma提出了收购要约** Truist分析师表示，与该公司目前约67亿美元的市值相比，70亿美元的估值显得“偏低”** Truist指出，LNTH将补充Curium在神经内分泌癌和前列腺癌领域已有的放射性药物产品组合** 美国食品药品监督管理局（FDA）于3月批准了Lantheus公司成像剂Pylarify TruVu的新剂型(link)，用于检测前列腺癌 ** Truist表示，LNTH仍“在多元化增长动力的推动下，是一个被低估且极具吸引力的营收/利润增长重启故事”，且其PET成像业务线的报销前景正在改善** 该券商表示，投资者会将每股115至125美元视为“更易接受的溢价/收购价位”** 截至上周五收盘，该股年内累计涨幅近55% (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}